Literature DB >> 16633200

Continuation and maintenance electroconvulsive therapy for the treatment of depressive illness: a response to the National Institute for Clinical Excellence report.

Melissa Frederikse1, Georgios Petrides, Charles Kellner.   

Abstract

Continuation and maintenance electroconvulsive therapy (ECT) is used to prevent relapse and recurrence of depressive episodes in those patients who have failed previous continuation and/or maintenance pharmacotherapy and who have also responded to an acute course of ECT. These patients frequently have histories of medication-resistant depression, medication intolerance, and/or comorbid medical conditions that complicate the management of their psychiatric illness. Previous studies of continuation and maintenance ECT, mostly consisting of case reports and retrospective chart reviews, as well as several prospective studies, support the practice of continuation and maintenance ECT as a viable treatment option for these difficult-to-treat patients. However, continuation and maintenance ECT have come under fire recently because of concerns of insufficient controlled studies demonstrating its efficacy, its long-term benefits, and its risks. This article thus reviews the most recent data available on the use of continuation and maintenance ECT in the treatment of depressive disorders. Although few new prospective controlled studies exist in the literature, published and emerging data continue to support the use of continuation and maintenance ECT, particularly in those individuals with medication-refractory, ECT-responsive, and relapse-prone depression.

Entities:  

Mesh:

Year:  2006        PMID: 16633200     DOI: 10.1097/00124509-200603000-00003

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  7 in total

Review 1.  Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature.

Authors:  Georgios Petrides; Kristen G Tobias; Charles H Kellner; Matthew V Rudorfer
Journal:  Neuropsychobiology       Date:  2011-07-29       Impact factor: 2.328

2.  The FDA and ECT.

Authors:  William M McDonald; Richard D Weiner; Laura J Fochtmann; W Vaughn McCall
Journal:  J ECT       Date:  2016-06       Impact factor: 3.635

3.  Toward individualized post-electroconvulsive therapy care: piloting the Symptom-Titrated, Algorithm-Based Longitudinal ECT (STABLE) intervention.

Authors:  Sarah H Lisanby; Shirlene Sampson; Mustafa M Husain; Georgios Petrides; Rebecca G Knapp; W Vaughn McCall; Robert C Young; Joan Prudic; Charles H Kellner
Journal:  J ECT       Date:  2008-09       Impact factor: 3.635

4.  The drugs don't work? antidepressants and the current and future pharmacological management of depression.

Authors:  Elizabeth Penn; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

5.  Preventing recurrent depression: long-term treatment for major depressive disorder.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

6.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

7.  Magnetic seizure therapy for treatment-resistant depression.

Authors:  Jiangling Jiang; Caidi Zhang; Chunbo Li; Zhimin Chen; Xinyi Cao; Hongyan Wang; Wei Li; Jijun Wang
Journal:  Cochrane Database Syst Rev       Date:  2021-06-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.